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Efficacy and safety of Colchicine in inflammatory skin diseases: a retrospective, 
monocentric study in a large tertiary center 
 
Abstract 
Introduction: 
Colchicine is an ancient, but rarely used drug. Little data exists on its efficacy and safety in 
dermatologic patients. The objective of our study was to determine whether colchicine 
showed favorable efficacy and safety in our patients during the last 20 years.  
Methods: 
The hospital database was searched for patients treated with colchicine  
in the last 20 years (January 1, 1998 to December 31, 2017). Overall, total of 41 patients were 
included in our study. 
Results:  
In 63.4% of all patients, either a complete response or an improvement of disease was 
observed. Adverse events occurred rarely.  
Disscussion: 
Colchicine is an effective and safe treatment.  
 
Keywords: Colchcine, Kolchizin, inflammatory dermatoses, neutrophils, neutrophilic 
dermatoses 
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Introduction 
Colchicine is one of the oldest drugs that is currently used in dermatology. The first 
documented use goes back to 1500 BC, where dapsone has was used for joint swelling in 
Egypt.[1] The first official report of successful treatment of gout with colchicine was 
published by Baron Anton von Storck in 1793.[2] 
It  is extracted from the herbaceous plant Colchicum autumale.[3] While colchicine appears 
initially as pale yellow, after UV- exposure, a conversion to different photoisomers takes 
place and the substance darkens.[3] After one hour plasma concentrations are reached and 
after 10 hours half of the concentration is metabolized by the liver.[4, 5] It interacts with the 
CYP3A4 enzyme and can therefore change the bioavailability of other drugs as macrolides, 
cyclosporine or ketoconazol.[6] 
Colchicine exhibits its anti-inflammatory properties through numerous mechanisms of action. 
Colchicine interferes with the formation of microtubules and increases intracellular cyclic 
adenosine monophosphate causing suppression of leukocyte function.[7] Colchicine impairs 
chemotaxis, migration and phagocytic capability of neutrophils,[8, 9] and inhibits DNA 
synthesis.[10, 11] Also degranulation of mast cells can be interrupted.[12] 
The use of colchicine is established for the treatment of gout,[13] atrial fibrillation,[14] 
pericarditis,[15, 16] familial Mediterranean fever,[17] posttransplant capillary leak syndrome 
and renal failure.[18] Possible protective benefits in stroke/TIA,[19] atherosclerotic 
cardiovascular disease,[20, 21] and periodontal tissue destruction[22] have been described.  
Additionally, this traditional drug has been reported to be beneficial in numerous other 
diseases, such as amyloidosis,[23] Wells' Syndrome,[24] Schamberg's disease,[25] junctional 
epidermolysis bullosa,[26] epidermolysis bullosa acquisita,[27] Hidradenitis suppurativa,[28] 
lichen planus pigmentosus,[29] aphthous stomatitis (apthosis), Behcets syndrome,[30] 
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condylomata acuminate (as topical solution), palmoplantar pustulosis, psoriasis, scleroderma, 
urticarial vasculitis as well as sweet syndrome,[3] polychondritis.[31]  
In a review of Robinson et al. the most common indications and their evidence were analyzed 
(Table 1).[32] 
In our department, we administered colchicine for 3 main indications: leucocytoclastic (small 
vessel) vasculitis, Behcet’s disease and recurrent benign aphthosis. 
Vasculitis has been an indication for colchicine for a long time.  In a case series, 9 of 13 
participants (69.2%) with leucocytoclastic vasculitis achieved disease control.[33] In a report 
of 6 patients with necrotizing vasculitis, 5 patients showed clinical improvement.[34] In a 
retrospective study (n=57).[35] Yet, the only prospective, randomized controlled trial (n= 20) 
could not yet prove significant therapeutic effect of colchicine.[36]  
In a prospective, open, cross-over trial with 20 patients with recurrent aphthous stomatitis 
(aphthosis), 19 patients showed improvement under 0.5mg colchicine three times daily.[37] A 
case series with 3 patients reported similar efficacy.[38] 
For Behcet’s disase a double-blind, randomized, placebo-controlled trial (n=116) showed a 
high efficacy of colchicine in this disease.[39] Several other studies came to similar 
results.[40-42]  
Besides its efficacy, several side effects have been described. Even though colchicine is 
generally well tolerated, gastrointestinal toxicity, including diarrhea, nausea and vomiting can 
occur after intake.[3, 43] Hepatotoxicity has been described, especially when concomitant 
intake of other medications that interact with CYP3A4, i.e. macrolides, has taken place.[44] 
Feared complications included anemia, neutropenia, rhabdomyolysis[45] as well as 
neuromyopathy.[46] Overdoses can be potentially lethal.[47]  
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With focus on young patients, azoospermia[48] as well as infertility[49]  have been associated 
with colchicine intake. Yet even though cytogenetic effects have been shown in animals, there 
is no data that suggests an increased risk of birth defects[49-51]. A single case of trisomy 21 
after parental use has been reported [52] 
The objective of our study was to determine whether colchicine showed favorable efficacy 
and safety in our patients during the last 20 years.   
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Methods 
Data acquisition  
Permission was granted by the cantonal ethic commission (BASEC-Nr. ID 2018-00854). 
Using the hospital data base, a search for patients that were treated with Colchicine at the 
Department of Dermatology at the University Hospital Zurich in the last 20 years 
(01.01.1998-31.12.2017) was performed. 67 patients matched these criteria. 2 were younger 
than 18 years and had to be excluded, 20 patients did not have follow-up visits. In 4 cases the 
data set required for analysis was incomplete (Figure 1). Overall, data from 41 patients were 
analyzed. 
 
The primary objective was to evaluate treatment efficacy- as judged by the physician. 
Treatment response was categorized into 4 groups (complete response, improvement of 
disease, stable disease and progression of disease). In the majority of cases treatment response 
was measured after 3 months. However, if colchicine intake was terminated sooner despite 
treatment success, treatment response was considered as success (either complete response or 
improvement of disease). The secondary objective was to evaluate adverse events described 
during treatment with colchicine. Other parameters as age, gender, diagnosis, dosage, duration 
of intake, and previous treatments were analyzed.  
 
Statistical analysis 
The D'Agostino & Pearson omnibus normality test, the Shapiro-Wilk normality test, and the 
Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefor p value) were used to for 
normality testing. For statistical analysis the Kruskal-Wallis-Test or, if appropriate, the Mann 
Whitney U test were performed.   
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Results 
41 patients were included in our study. 17 were male, 24 female. The average age was 50±18 
years, the youngest was 18 years, the oldest 88 years. Previous systemic treatments included 
most of the time dapsone (n=11) and systemic steroids (n=9). 4 patients had colchicine 
previously but stopped due to various reasons. The target dose was in most cases 1 mg 
(n=26), 12 patients received 1.5 mg and only 3 patients had a dosage of 2 mg.In most cases, 
colchicine was either first- or second line treatment. In 19 cases systemic steroids were used 
concomitantly (Table 2). 15 patients were treated with colchicine for aphthosis, 11 patients for 
vasculitis, and 7 for Behcet’s disease. Other diagnoses included lupus erythematodes, sweet 
syndrome, gout, hypereosinophilic dermatitis, rosacea, Well’s syndrome, and urticarial (Table 
2, Figure 2A). 
In 6 out of 15 patients with from aphthosis an improvement was seen. 2 had a complete 
response and in 4 a stable disease was observed. A progression of disease was found in 3 
patients. In patients suffering from small vessel vasculitis (IgA positive and IgA negative) 
overall 7 patients showed a treatment response to colchicine, while only 4 had a stable disease 
or progression of disease. Complete responses were also seen in patients with rosacea (n=1), 
gout (n=1) and sweet syndrome (n=1) (Table 3, Figure 2B). 
 
Overall, 8 patients (19.5%) had a complete response, 18 (43.9%) showed an improvement, 11 
(26.8%) had stable disease and in 4 cases (9.8%) a progression of disease was found (Figure 
2C). 
 
The most common adverse events included diarrhea (n=6, 13.3%), nausea (n=4, 8.9%) and 
vomiting (n=2, 4.4%). All other side effects were only seen in less than 5% of all patients and 
included, alopecia, an allergic type I reaction (not otherwise specified), stomatitis, visual 
8 
 
deficiency, pregnancy, peripheral neuropathy, myopathy/rhabdomylosis, headache, vaginal 
bleeding, arthralgia, vertigo and pruritus (Table 4). 
  
Increased liver enzymes were seen in 8 patients (27.6%), which had normal transaminases 
before initiation of colchicine treatment. Kidney function became pathological in 5 patients 
(11.1%). There were no abnormal thyroid parameters observed. Also no patient yielded 
increased cholesterol or triglycerides (Table 4). 
 
The reasons for termination of therapy included adverse events in 2 cases, success of therapy 
with complete response in 14 cases. 10 patients stopped taking colchicine due to failure of 
treatment. 2 patients had other reasons. In 10 patients no reasons was disclosed or 
documented. 3 patients were still on treatment during our analysis. (Table 3).  
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Discussion 
The objective of our study was to determine whether colchicine showed favorable efficacy 
and safety in our patients during the last 20 years. In this analysis, we found that in 63.4% of 
all patients, either a complete response or improvement of disease was observed. Colchicine 
was effective in patients with aphthosis, small vessel vasculitis and Behcet’s disease. The 
number of patients in other diseases was too small to draw any conclusions. It remains unclear 
what feature distinguished patients who showed a non-favorable treatment response (stable 
disease or progression of disease). Possibly, bad adherence might account for failure of 
treatment in some patients, but this remains speculative. Our results are in line with several 
previous studies that showed a high efficacy, especially among patients with aphthosis and 
Behcet’s disease. Also in vasculitis our data support the majority of positive reports and are in 
contrast to the only randomized, controlled, double-blind trial that did not find efficacy of 
colchicine.[36] 
Our study has several limitations, including the retrospective, monocentric design. No 
correlation of weight and dosage was performed, as weight was seldom documented.  
In contrast to previous publications[43, 53] where adverse events especially of the GI tract 
occurred, this was not the case in our study. In fact, adverse events were overall, surprisingly, 
seldom. A possible reason remains the rather low dose prescribed in our clinic (mostly 1.0 mg 
daily) as compared to the widely reported 2 or 3mg daily in the literature. 
Drugs that are used primarily as first- or second-line therapies have higher success rates 
compared to medications that are administered after several therapies have previously failed. 
Possibly this is another reason for the good efficacy seen was that colchicine was used in most 
cases as either primary or secondary treatment.  
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Even though colchicine belongs to the oldest drugs used in dermatology, there is still much to 
learn from it. Larger, prospective clinical trials need to be performed to receive a better 
insight of this high-potential drug. 
  
11 
 
Acknowledgements: 
- 
 
Funding details: 
There has been no funding. 
 
Declaration of interest statement: 
All authors state that they don’t have a conflict of interest. 
  
12 
 
References: 
1. Graham, W. and J.B. Roberts, Intravenous colchicine in the management of 
gouty arthritis. Ann Rheum Dis, 1953. 12(1): p. 16-9. 
2. Malkinson, F.D., Colchicine. New uses of an old, old drug. Arch Dermatol, 
1982. 118(7): p. 453-7. 
3. Sullivan, T.P., L.E. King, Jr., and A.S. Boyd, Colchicine in dermatology. J Am 
Acad Dermatol, 1998. 39(6): p. 993-9. 
4. Wallace, S.L., B. Omokoku, and N.H. Ertel, Colchicine plasma levels. 
Implications as to pharmacology and mechanism of action. Am J Med, 1970. 
48(4): p. 443-8. 
5. Hunter, A.L. and C.D. Klaassen, Biliary excretion of colchicine. J Pharmacol 
Exp Ther, 1975. 192(3): p. 605-17. 
6. Finkelstein, Y., et al., Colchicine poisoning: the dark side of an ancient drug. 
Clin Toxicol (Phila), 2010. 48(5): p. 407-14. 
7. Margulis, L., Colchicine-sensitive microtubules. Int Rev Cytol, 1973. 34: p. 
333-61. 
8. Phelps, P., Polymorphonuclear leukocyte motility in vitro: IV. Colchicine 
inhibition of chemotactic activity formation after phagocytosis of urate crystals. 
Arthritis Rheum, 2008. 58(2 Suppl): p. S25-33. 
9. Dallaverde, E., P.T. Fan, and Y.H. Chang, Mechanism of action of colchicine. 
V. Neutrophil adherence and phagocytosis in patients with acute gout treated 
with colchicine. J Pharmacol Exp Ther, 1982. 223(1): p. 197-202. 
10. Fitzgerald, P.H. and L.A. Brehaut, Depression of DNA synthesis and mitotic 
index by colchicine in cultured human lymphocytes. Exp Cell Res, 1970. 59(1): 
p. 27-31. 
11. Hell, E. and D.G. Cox, Effects of colchicine and colchemid on synthesis of 
deoxyribonucleic acid in the skin of the guinea pig's ear in vitro. Nature, 1963. 
197: p. 287-8. 
12. Dalbeth, N., T.J. Lauterio, and H.R. Wolfe, Mechanism of action of colchicine 
in the treatment of gout. Clin Ther, 2014. 36(10): p. 1465-79. 
13. Kwon, O.C., et al., Risk of Colchicine-Associated Myopathy in Gout: Influence 
of Concomitant Use of Statin. Am J Med, 2017. 130(5): p. 583-587. 
14. Lennerz, C., et al., Colchicine for primary prevention of atrial fibrillation after 
open-heart surgery: Systematic review and meta-analysis. Int J Cardiol, 2017. 
249: p. 127-137. 
15. Imazio, M., Colchicine for pericarditis. Trends Cardiovasc Med, 2015. 25(2): p. 
129-36. 
16. Chhabra, L. and D.H. Spodick, Colchicine for pericarditis. Am J Health Syst 
Pharm, 2014. 71(23): p. 2012-3. 
17. Ozer, I., et al., Association between colchicine resistance and vitamin D in 
familial Mediterranean fever. Ren Fail, 2015. 37(7): p. 1122-5. 
18. Cocchi, E., et al., Colchicine: An Impressive Effect on Posttransplant Capillary 
Leak Syndrome and Renal Failure. Pediatrics, 2019. 143(5). 
19. Khandkar, C., K. Vaidya, and S. Patel, Colchicine for Stroke Prevention: A 
Systematic Review and Meta-analysis. Clin Ther, 2019. 41(3): p. 582-590 e3. 
20. Nidorf, S.M. and P.L. Thompson, Why Colchicine Should Be Considered for 
Secondary Prevention of Atherosclerosis: An Overview. Clin Ther, 2019. 
41(1): p. 41-48. 
21. Tsivgoulis, G., et al., The Role of Colchicine in the Prevention of 
Cerebrovascular Ischemia. Curr Pharm Des, 2018. 24(6): p. 668-674. 
13 
 
22. Aral, C.A., et al., Effects of colchicine on gingival inflammation, apoptosis, and 
alveolar bone loss in experimental periodontitis. J Periodontol, 2018. 89(5): p. 
577-585. 
23. Portincasa, P., Colchicine, Biologic Agents and More for the Treatment of 
Familial Mediterranean Fever. The Old, the New, and the Rare. Curr Med 
Chem, 2016. 23(1): p. 60-86. 
24. Puzas, A.I., et al., Wells' Syndrome Successfully Treated with Colchicine. 
Case Rep Dermatol, 2017. 9(2): p. 65-69. 
25. Cavalcante, M., et al., Schamberg's disease: case report with therapeutic 
success by using colchicine. An Bras Dermatol, 2017. 92(2): p. 246-248. 
26. Kim, M., et al., Colchicine may assist in reducing granulation tissue in 
junctional epidermolysis bullosa. Int J Womens Dermatol, 2016. 2(2): p. 56-59. 
27. Adachi, A., et al., Oral colchicine monotherapy for epidermolysis bullosa 
acquisita: Mechanism of action and efficacy. J Dermatol, 2016. 43(11): p. 
1389-1391. 
28. Armyra, K., et al., Hidradenitis suppurativa treated with tetracycline in 
combination with colchicine: a prospective series of 20 patients. Int J 
Dermatol, 2017. 56(3): p. 346-350. 
29. Cozzani, E., et al., Could colchicine represent a new therapeutic approach for 
lichen planus pigmentosus? Dermatol Ther, 2019. 32(2): p. e12809. 
30. Cocco, G., D.C. Chu, and S. Pandolfi, Colchicine in clinical medicine. A guide 
for internists. Eur J Intern Med, 2010. 21(6): p. 503-8. 
31. Puechal, X., et al., Relapsing polychondritis. Joint Bone Spine, 2014. 81(2): p. 
118-24. 
32. Robinson, K.P. and J.J. Chan, Colchicine in dermatology: A review. Australas 
J Dermatol, 2018. 59(4): p. 278-285. 
33. Callen, J.P., Colchicine is effective in controlling chronic cutaneous 
leukocytoclastic vasculitis. J Am Acad Dermatol, 1985. 13(2 Pt 1): p. 193-200. 
34. Hazen, P.G. and B. Michel, Management of necrotizing vasculitis with 
colchicine. Improvement in patients with cutaneous lesions and Behcet's 
syndrome. Arch Dermatol, 1979. 115(11): p. 1303-6. 
35. Jachiet, M., et al., The clinical spectrum and therapeutic management of 
hypocomplementemic urticarial vasculitis: data from a French nationwide 
study of fifty-seven patients. Arthritis Rheumatol, 2015. 67(2): p. 527-34. 
36. Sais, G., et al., Colchicine in the treatment of cutaneous leukocytoclastic 
vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol, 
1995. 131(12): p. 1399-402. 
37. Katz, J., et al., Prevention of recurrent aphthous stomatitis with colchicine: an 
open trial. J Am Acad Dermatol, 1994. 31(3 Pt 1): p. 459-61. 
38. Ruah, C.B., J.R. Stram, and W.D. Chasin, Treatment of severe recurrent 
aphthous stomatitis with colchicine. Arch Otolaryngol Head Neck Surg, 1988. 
114(6): p. 671-5. 
39. Yurdakul, S., et al., A double-blind trial of colchicine in Behcet's syndrome. 
Arthritis Rheum, 2001. 44(11): p. 2686-92. 
40. Aktulga, E., et al., A double blind study of colchicine in Behcet's disease. 
Haematologica, 1980. 65(3): p. 399-402. 
41. Masuda, K., et al., Double-masked trial of cyclosporin versus colchicine and 
long-term open study of cyclosporin in Behcet's disease. Lancet, 1989. 
1(8647): p. 1093-6. 
42. Wechsler, B., [Colchicine and Behcet's disease: an efficacious treatment 
finally recognized!]. Rev Med Interne, 2002. 23(4): p. 355-6. 
14 
 
43. Ahern, M.J., et al., Does colchicine work? The results of the first controlled 
study in acute gout. Aust N Z J Med, 1987. 17(3): p. 301-4. 
44. Abbott, C.E., R. Xu, and S.H. Sigal, Colchicine-Induced Hepatotoxicity. ACG 
Case Rep J, 2017. 4: p. e120. 
45. Arslan, M.N., et al., Colchicine-Induced Rhabdomyolysis: An Autopsy Case. 
Am J Forensic Med Pathol, 2016. 37(2): p. 57-9. 
46. Olmos-Martinez, J.M., et al., Acute Colchicine-induced Neuromyopathy in a 
Patient Treated with Atorvastatin and Clarithromycin. Eur J Case Rep Intern 
Med, 2019. 6(3): p. 001066. 
47. Hirayama, I., et al., A critically ill patient after a colchicine overdose below the 
lethal dose: a case report. J Med Case Rep, 2018. 12(1): p. 191. 
48. Merlin, H.E., Azoospermia caused by colchicine--a case report. Fertil Steril, 
1972. 23(3): p. 180-1. 
49. M Ehrenfeld, A.B., M Levy, M Eliakim Colchicine: infertility incidence study. Br 
J Obstet Gynaecol, 1987(94): p. 1186-1191. 
50. Katsilambros, Y., Colchicine in the preventive treatment of rubella 
embryopathy. Arch Inst Pasteur Hellen, 1963(9): p. 97. 
51. Rabinovitch, O., et al., Colchicine treatment in conception and pregnancy: two 
hundred thirty-one pregnancies in patients with familial Mediterranean fever. 
Am J Reprod Immunol, 1992. 28(3-4): p. 245-6. 
52. AN Cestari, J.V.F., Y Yonenago. , A case of human reproductive abnormalities 
possibly induced by colchicine treatment. Rev Brazil Biol, 1965. 25: p. 253-
256. 
53. Morris, I., G. Varughese, and P. Mattingly, Colchicine in acute gout. BMJ, 
2003. 327(7426): p. 1275-6. 
